AI assistant
PLUS THERAPEUTICS, INC. — Director's Dealing 2016
Feb 1, 2016
34301_dirs_2016-02-01_f276c0b5-c7f0-4d74-ac89-789462ea699d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CYTORI THERAPEUTICS, INC. (CYTX)
CIK: 0001095981
Period of Report: 2016-01-28
Reporting Person: KESTEN STEVEN (Exec VP and Chief MO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-01-28 | Common Stock | A | 47000 | — | Acquired | 49201 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 6000 | Indirect |
Footnotes
F1: Shares held directly by Steven Kesten and Barbara Mary Kesten, trustees of The Kesten Living Trust Dated January 31, 2002, a trust for the benefit of the Reporting Person and the Reporting Person's spouse, for which the Reporting Person and the Reporting Person's spouse serve as trustees.
F2: Represents shares of Common Stock issued under the Company's 2015 Executive Management Incentive Compensation Plan and vested based upon level of achievement of certain metrics related to clinical trial enrollment and the Company's financial position for the performance period of May 26, 2015 to December 31, 2015. All shares were issued pursuant to the Company's 2014 Equity Incentive Plan.